INTRODUCTION
1. In order to assess potential abnormalities in the control of mucosal proliferation, 30 patients with Barrett's oesophagus were studied in order to evaluate the presence and distribution of epidermal growth factor, iransforming growth factor-a -and epidermal growth factor receptor to determine the Ki-67 labelling index in the affected oesophageal mucosa. Serial sections were analysed immunohistochemically. Ten of the patients had adenocarcinoma in the Barrett's mucosa and the other 20 had differing histological types of Barrett's mucosa (10, intestinal-type; 10, fundic-or cardiac-type).
2. The expression of transforming growth factor-a, epidermal growth factor and epidermal growth factor receptor was increased and the Ki-67 labelling index was higher in Barrett's mucosa compared with normal gastric mucosa. The 'intestinal-type' of Barrett's mucosa had the greatest expression of transforming growth factor-a, epidermal growth factor receptor and the highest Ki-67 labelling index compared with the other types of Barrett's metaplasia. Five cases of 'intestinal-type' Barrett's metaplasia had especially high Ki-67 labelling indices and these patients over-expressed both transforming growth factor-a and epidermal growth factor receptor. The patients with adenocarcinomas in the Barrett's mucosa also over-expressed transforming growth factor-a and epidermal growth factor receptor, but not epidermal growth factor, compared with normal gastric mucosa.
3. In conclusion, both normal gastric mucosa and Barrett's mucosa have potential autocrine growth regulatory mechanisms, but Barrett's mucosa has increased expression of both of the measured ligands and of the epidermal growth factor receptor.
In 1950, Barrett [l] , in his paper "Chronic peptic ulcer of the oesophagus and 'oesophagitis"', drew attention to a condition in which the lower portion of the oesophagus was lined by a columnar epithelium. Subsequently, it was recognized that Barrett's mucosa has a 30-40-fold increased risk of adenocarcinoma compared with the normal oesophagus [2-51. As a result, many attempts have been made prospectively to assess these lesions for malignant potential [6-91. Unfortunately, none of the available screening procedures have had any documented impact on the prognosis of this disease [2, 4, 5, . This is, in part, because the events that control cellular proliferation, differentiation and oncogenesis in the oesophagus have until recently been poorly understood. The importance of growth factors [for example, epidermal growth factor (EGF) and transforming growth factor-a (TGFa)] and their receptor [epidermal growth factor receptor (EGF-R)] in controlling cellular growth has been documented in other gastrointestinal tissues [13] [14] [15] .
EGF and TGFa are part of the EGF family because they have three common characteristics: high-affinity binding to EGF-R, production of mitogenic responses in EGF-sensitive cells, and a similar primary structure containing six half-cystine residues [16, 171 . It is believed that EGF and TGFa exert their oncogenic effects primarily by induction of intranuclear c-fos and c-myc genes, which are 'proto-oncogenes' [18] [19] [20] , but many other potential oncogenic proteins are also stimulated, sought to determine the presence and distribution of EGF, TGFa and EGF-R in Barrett's mucosa in an attempt to define the role of these growth factors in the development of oesophageal cancer. This study has therefore assessed: (1) the expression of EGF, TGFa and EGF-R in Barrett's mucosa and adenocarcinomas arising from Barrett's mucosa; and (2) cellular proliferation by using the Ki-67 labelling index [27] .
METHODS

Patients
Thirty patients with histologically proven Barrett's I columnar-lined oesophageal mucosa, who were attending an annual endoscopic follow-up screening programme, were studied. Eighteen were women and 12 were men, with a mean age of 65 years (range 32-74 years).
Biopsies and irnrnunohistochernistry
The patients were endoscoped and biopsies were taken from areas of columnar (Barrett's) mucosa and any areas of frank mucosal neoplasia. In addition, all patients had a biopsy taken from benign cardiac gastric mucosa [28] .
Three immediately adjacent biopsies were taken from each oesophagus (and gastric cardia). The biopsies were snap-frozen in the endoscopy room, and 6 p m cryostat sections were cut. Four serial sections were stained immunohistochemically to demonstrate EGF, TGFa, EGF-R and the Ki-67 labelling index. The antibodies were supplied by Oncogene Science (Manhaset, NY, U.S.A.): all were IgG monoclonal antibodies which had specific binding to their substrate (no cross-reactivity of EGF with TGFa or vice versa) [29] . The antigen-antibody reaction was visualized by the modified strepavidin technique [30] .
The biopsies were classified according to the type of metaplasia [2] and dysplasia [28] . Mucosa with fundicor cardiac-type metaplasia were grouped together because they have a low risk of malignant transformation, unlike intestinal-type metaplasia [2, 281. Therefore three categories of Barrett's mucosa comprised: (i) fundic-or cardiac-type Barrett's mucosa, (ii) intestinal-type Barrett's mucosa, and (iii) adenocarcinoma. In these categories mucosa demonstrating dysplasia was noted separately.
Positive EGF and TGFa staining was graded according to criteria which we developed. Five randomly viewed areas of at least 200 consecutive nucleated epithelial cells were independently assessed by two observers. The sections were considered positive only if the number of epithelial cells which had at least 1 + staining was > 10% of the total epithelial cells. The intensity of staining was graded as 0-3 [0, no staining, 1 + , weakly positive, 2 + , moderately positive (cytoplasm positive but unstained cytoplasm also visible), 3 + , strongly positive (entire cytoplasm densely stained)]. The grade considered to be 3 + was stained as densely as simultaneously stained (control) submandibular gland tissue. Some sections of differing staining intensities exhibited membranous staining in addition to cytoplasmia staining, and this finding was noted separately. In some cases, the staining intensity was heterogeneous and a mean intensity per section was calculated. For example, if 100 cells were counted in one section and the number of cells of each intensity was as follows: 0 = 4, 1 = 14, 2 = 78, 3 = 4, the mean count was calculated as (0 X 4) + (1 x 14)+(2 X 78) +(3 X 4) = 182/ 100. Therefore the mean intensity in this section was rounded up to '2'.
EGF-R-positive staining was graded by a modified method described previously for bladder epithelium [3 13 . Sections (consisting of five randomly viewed areas of 100 consecutive nucleated epithelial cells) were considered positive only if > 10% of all cells had at least 1 + staining, and negative if < 10% of cells stained positively. The intensity of surface membrane staining was graded as 0-3 + [3 + being considered equal to the simultaneously stained positive control tissue (oesophageal squamous carcinoma) and 2 + equal to benign squamous oesophageal mucosa]. Some sections had a heterogeneous staining intensity and the mean intensity was calculated per section, as above. Although diffuse cytoplasmic staining was visible in many epithelial cells, there was little difference between sections.
The Ki-67 labelling index was calculated by expressing the number of positively stained epithelial nuclei as a ratio of the total population of epithelial cells. A minimum of 500 epithelial cells was counted [27, 32] .
The discrepancy between the two sets of independent counts for the 60 sections (30 Barrett's mucosa+30 cardiac mucosa) was less than 5%.
Statistics
Spearman rank analysis was used to assess the correlation between histological appearances and expression of EGF, TGFa and EGFR. The data were not normally distributed, so that Kruskal-Wallis analysis was used to compare the variance of each of the variables (EGF, TGFa, EGF-R expression and the Ki-67 labelling index) with the different histological groups. Wilcoxon's paired test compared the expression of EGF, TGFa and EGF-R in Barrett's biopsies with corresponding biopsies from normal cardiac mucosa in the same patient.
RESULTS
Ten patients were proven to have adenocarcinoma arising from areas of Barrett's mucosa. Ten patients had distinctive 'intestinal-type' Barrett's mucosa and another ten had fundic-or cardiac-type Barrett's mucosa.
The histological grading of the three categories of Barrett's mucosa was significantly correlated with TGFa and EGF-R expression ( P < 0.05) and the Ki-67 labelling index (P<O.Ol), but not with EGF expression (P=O.4). Similarly, the Ki-67 labelling index was correlated with TGFa and EGF-R expression (P<0.05), but not with EGF expression ( P = 0.2).
The mean expression of EGF did not change significantly between the three histological groups ( P = 0.5) (Fig. 1) . However, TGFa expression increased stepwise from low levels of fundic-or cardiac-type mucosa, to moderate levels in intestinal-type mucosa, and moderate to high levels in adenocarcinoma (P<O.O5) (Fig. 2) . Similarly, EGF-R expression was low in fundic-or cardiac-type mucosa and high in both intestinal-type mucosa and adenocarcinoma (P<O.O5) (Fig. 3) . The Ki-67 labelling index was very low in fundic-or cardiac-type mucosa, moderately high in intestinal-type mucosa and very high in adenocarcinoma ( P < 0.01) (Fig. 4) .
There was no statistial difference between EGF, TGFa and EGF-R expression in fundic-type Barrett We found that the Ki-67 labelling index was low in some sections which stained strongly for the two peptides but showed little staining for EGF-R.
Five of the intestinal-type Barrett's mucosa showed moderate to severe dysplasia and had moderate or strong expression of both TGFa and EGF-R. These five mucosae also had very high Ki-67.labelling indices with a mean of 29% (range 20-3670) compared with normal gastric mucosa (mean 6%), fundic-type Barrett's mucosa (mean 8%) and the other five intestinal-type Barrett's mucosa (mean 15%) and Barrett's adenocarcinoma (mean 27%). All other cases of Barrett's mucosa had at most mild dysplasia.
DISCUSSION
It has been reported previously that EGF, TGFa and EGF-R are associated with mitogenesis and oncogenesis ' [13, 14, We found a stepwise increase in expression of TGFa and EGF-R from fundic-type Barrett's mucosa through intestinal-type Barrett's mucosa to Barrett's adenocarcinoma. It is interesting to note that the five patients with moderate to severe dysplasia showed high TGFa and EGF-R expression as well as high Ki-67 labelling indices, compatible with involvement of the ligand and receptor in the pre-neoplastic changes of the oesophageal mucosa. These findings are consistent with previous reports which indicate that intestinal-type Barratt's mucosa is more liable to undergo increased proliferation and neoplastic change compared with either fundic-or cardiac-type mucosa [2, 3, 9, 46, 47] .
The simultaneous over-expression of TGFa and EGF-R may not be by chance. TGFa is known to increase the level of TGFa mRNA in an 'autocrine-loop' in neoplastic cells [41] and it has been postulated that under certain circumstances TGFa may induce EGF-R expression also [48] . These changes may reflect the failure of autoregulation of TGFa expression by molecules such as anti-oncogenes [ 141.
There are three mechanisms whereby co-expression of TGFa and EGF-R can lead to increased mitogenesis and oncogenesis [49] . TGFa may stimulate receptors on the same cell, activating an intracellular cascade of cytoplasmic and nuclear proliferation-inducing effects (autocrine mechanism). It has also been reported that cell-cell adhesion, mediated by binding of membraneanchored TGFa to EGF-R, may promote cell proliferation ('juxtacrine' mechanism) [50] . In addition, TGFa from one cell can bind to the EGF-R in nearby cells, although it has been suggested that expression of TGFa and EGF-R would have to be very high, since there is much dilution of ligand in the extracellular space (paracrine mechanism) [37] . Our study does not permit conclusions about which mechanism is predominant in the growth regulation of normal or abnormal oesophageal mucosa.
In the present study we have found a significant correlation between the Ki-67 labelling index and the expression of TGFa and EGF-R, but not the expression of EGF, consistent with the finding that staining for EGF does not differ significantly between the different types of Barrett's mucosa or Barrett's neoplasia. However, EGF is demonstrable and it is not possible to exclude the possibility that EGF may be exerting a synergistic action, because EGF-dependent stimulation also increases the level of TGFa mRNA (auto-induction) [51] . In addition, EGF may induce signal amplification once cells have already been transformed by TGFa [52] . In general, it is likely that EGF and TGFa augment or amplify each other's actions [14, 12, 49, 53] .
Although the two peptides bind to EGF-R, TGFa has different conformational, receptor-binding and processing properties compared with EGF [54, 551. Therefore it seems possible that these properties contribute to the greater oncogenic effects of TGFa in epithelial tissue [13, 37,42,51,56-581. It seems probable that EGF-R is produced in the Barrett's mucosa, as its mRNA has been demonstrated in a case of Barrett's oesophagus [59] . Moreover, abundant TGFa mRNA and EGF-R mRNA is found in all gastric carcinoma cell lines [42] , all oesophageal squamous cell carcinoma lines [14, 60] and normal gastric and intestinal mucosa [61] , whereas EGF mRNA is reported in only 33% of gastric carcinomas and 50% of oesophageal squamous carcinomas and not at all in normal gastric mucosa.
In conclusion, Barrett's mucosa has features that indicate the possibility of autocrine growth regulation, as Barrett's mucosa (especially when dysplastic) and Barrett's neoplasia over-express TGFa and EGF-R. Barrett's mucosa therefore demonstrates a failure of important controlling mechanisms of epithelial cell proliferation 1621. Demonstration of TGFa and EGF-R in oesophageal mucosa may have prognostic as well as diagnostic potential, because the over-expression of TGFa and EGF-R has been shown to be inversely proportional to prognosis and depth of tumour invasion in oesophageal carcinomas and in the metastatic spread of gastric carcinomas [14, 53, 63] . 
